How Investors May Respond To 10x Genomics (TXG) Bringing AI-Powered Analysis Tools to Life Sciences

• On October 20, 2025, Anthropic and 10x Genomics announced a collaboration to integrate 10x's advanced analysis tools into Claude for Life Sciences, allowing researchers to interact with single cell and spatial biology data using natural language via the Model Context Protocol (MCP).
• This advancement reduces the technical barrier for life sciences researchers, potentially broadening adoption of 10x's technologies across institutions and accelerating data-driven scientific discovery.
• We'll now consider how making 10x Genomics’ analysis tools available through an AI-driven conversational interface may influence its investment narrative.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

10x Genomics Investment Narrative Recap

To be a shareholder in 10x Genomics, you need confidence that single-cell and spatial biology will see persistent growth, with innovation and usability driving platform adoption. The new AI collaboration with Anthropic, which brings natural language interfaces into the workflow, meaningfully addresses the usability hurdle for new and non-technical users, but is unlikely to immediately shift the company’s short-term revenue catalysts or offset the primary risk, continued pressure from academic and government funding constraints. Among recent developments, the launch of Xenium Protein on the Xenium Spatial platform stands out. This update allows simultaneous detection of RNA and protein in single cells, expanding use cases and aligning well with AI-enabled analysis by further broadening the types of complex data researchers can now explore using both the Claude interface and new product capabilities. On the other hand, investors should remember the ongoing challenge of shrinking research budgets and the risk that even innovative technology may struggle to overcome funding headwinds...

Read the full narrative on 10x Genomics (it's free!)

10x Genomics' narrative projects $688.4 million in revenue and $97.8 million in earnings by 2028. This requires 2.2% yearly revenue growth and a $182.4 million increase in earnings from the current -$84.6 million.

Uncover how 10x Genomics' forecasts yield a $15.08 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Seven members of the Simply Wall St Community estimated fair values for 10x Genomics, ranging from US$6.47 to US$40 per share. While many see potential in new technology, continued CapEx constraints in research funding could slow broader adoption and earnings momentum.

Explore 7 other fair value estimates on 10x Genomics - why the stock might be worth less than half the current price!

Build Your Own 10x Genomics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are the new gold rush. Find out which 34 stocks are leading the charge.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com